• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medical device tax: AdvaMed asks IRS to define “manufacturer”

Medical device tax: AdvaMed asks IRS to define “manufacturer”

March 23, 2011 By MassDevice staff

AdvaMed logo

The medical device industry is looking for some clarity from the IRS on the meaning of the word “manufacturer” as it applies to a tax contained in the health care reform law.

Attempting to make sure contract manufacturers and original equipment manufacturers are not taxed twice for the same product under the new medical device excise tax provision, the Advanced Medical Technology Assn. sent an 18-page letter to the federal tax agency asking that the IRS consider several AdvaMed recommendations on implementing the tax.

AdvaMed has been a staunch opponent of the tax since it was first bandied about as an idea in the contentious donnybrook around what became the Patient Protection and Affordable Care Act back in September 2009.

“AdvaMed and its member companies continue to believe the medical device excise tax is a serious burden for companies struggling to maintain America’s global leadership in the development of medical technology. But if the tax is implemented, it must be done consistent with the law’s intention and in a way that can be administered practically and efficiently by medical device companies and the IRS,” wrote Christopher White, AdvaMed’s general counsel.

The public comment period could be critical in shaping how the law is administered. In particular, AdvaMed is pushing for the IRS to clearly define what a manufacturer is under the tax. Because the medical device industry is heavily reliant on a vast network of component manufacturers, the possibility of a single product being taxed multiple times is possible under a broader definition. Including contract manufacturers in the excise tax formula could have broad implications for small contract and component manufacturers.

“AdvaMed recommends that the IRS retain the current definition of ‘manufacturer’ but clarify that manufacturing activities only involve physically transformative activities, including the re-processing or re-manufacturing of taxable medical devices,” White wrote. “AdvaMed further recommends that the IRS give consideration to the factors reflected in the contract manufacturing regulations in determining which of two parties to a contractual arrangement involving manufacturing is the manufacturer, rather than relying primarily on which party has legal title to the articles during the manufacturing process.”

The letter was submitted as part of a public comment period to the IRS on how the medical device tax will be administered. The 2.3 percent annual tax on U.S. sales goes into effect in 2013. AdvaMed officials said they will submit further public comment as the debate continues.

Filed Under: Healthcare Reform, News Well Tagged With: AdvaMed

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy